Bi­o­Lin­eRx’s Aphex­da ap­proved to aid stem cell trans­plants for mul­ti­ple myelo­ma pa­tients

Au­tol­o­gous stem cell trans­plan­ta­tion (AS­CT) is part of the stan­dard of care for pa­tients with mul­ti­ple myelo­ma. It’s a process in which a pa­tient’s own stem cells are re­moved and rein­tro­duced, of­ten af­ter treat­ment with chemother­a­py. But some pa­tients don’t make good can­di­dates.

Less than half of pa­tients have had trou­ble col­lect­ing tar­get num­bers of hematopoi­et­ic stem cells in one round, de­pend­ing on oth­er fac­tors, ac­cord­ing to Tel Aviv-based biotech Bi­o­Lin­eRx. The com­pa­ny hopes to change that with its new­ly ap­proved ther­a­py: Aphex­da, al­so known as motix­afor­tide.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER